Skip to main content
search

Acute Migraine

Hightower Clinical previously participated in a study evaluating an investigational drug for moderate to severe migraine. The goal was to bring faster and more effective relief to patients experiencing acute episodes.

                       

Evaluated a New Approach for Treating Migraine Pain

Migraines are intense headaches often accompanied by nausea, sensitivity to light and sound, and vision changes. They can significantly disrupt daily activities and lower the quality of life. Acute migraine treatment is essential for reducing the severity and duration of an attack.

To identify more effective treatment options, Hightower Clinical conducted a study evaluating an investigational drug. The study aimed to assess the safety and efficacy of the drug across multiple dose ranges in patients experiencing moderate to severe migraine episodes.

Current Status

Not Recruiting

Study Count

01

Study Information

Acute Migraine

Study NameProtocol NumberSponsor
Acute Migraine

KAL-AGT01-007

Alnylam

Frequently Asked Questions

1. What was the goal of the acute migraine clinical trial?

The study aimed to evaluate the safety and effectiveness of an investigational drug in relieving moderate to severe migraine attacks.

2. Who participated in the study?

Adults who experienced moderate to severe migraines were enrolled to assess the potential benefits of the study drug.

3. Is this clinical trial still enrolling patients?

No, the trial is currently not recruiting new participants.

Close Menu